Medical Cannabis Payment Solutions’ (REFG) Green is Designed to Grow

  • Proprietary payment platform customized for legal cannabis merchants makes it a gateway to the industry for electronic money transactions
  • CEO Jeremy Roberts says that Green platform takes state-sanctioned cannabis into the 21st century of electronic banking and financial services
  • Green platform offers ease of cash management to merchants while enabling consumers and patients to purchase electronically, even with cryptocurrency

Medical Cannabis Payment Solutions’ (OTC: REFG) Green platform, a top tier digital payment processing system, is designed to bring legalized cannabis and its cash management for licensed merchants and dispensaries into the world of digital financial services.

“What we’re launching is the very literal cure for the banking nightmare cannabis establishments face,” Jeremy Roberts, CEO of REFG, stated in a news release (http://cnw.fm/od3rP). “This checks every box, from regulatory compliance, security, affordability, ease of use, integration — you name it, we’ve responded.”

Among its key advantages are the money management system and the simple signup feature for consumers. Not only is it FinCEN-compliant, Green offers both merchants and customers an enticing platform to manage money for sellers and financial services for buyers.

For merchants, it can be integrated with most any existing point-of-sale system. Recurring billing for consumers can be set up, as well as money management features such as payroll. Green also offers ease of digital payments, tracking of customer sales and even internal payments. For consumers, the platform is easy to join for purchasing legalized cannabis products from licensed merchants or dispensaries, even using cryptocurrency, if desired. REFG has partnered with First Bitcoin Capital Corporation to ensure acceptance of virtual currencies (http://cnw.fm/MeyI7).

To create loyalty and drive repeat purchases, REFG can even brand its Green cards with the merchant’s name and logo.

For more information, visit the company’s website at www.MedicalCannabisPaymentSolutions.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Global Hemp Group, Inc. (CSE: GHG) (FRA: GHG) (OTC: GBHPF) Completes $1.5 Million Private Placement

  • Proceeds to be used for development of new cultivation and processing project in New Brunswick
  • A boost to operating capital
  • Canada plans to legalize the extraction of cannabinoids from hemp in mid-2018
  • Market for hemp CBD products is predicted to grow to $450 million by 2020

Global Hemp Group, Inc. (CSE: GHG) (FRANKFURT: GHG) (OTC: GBHPF), a company focused on the cultivation of hemp and cannabinoid extraction for both domestic and international markets, announced on March 7, 2018, that it had closed a non-brokered private placement, consisting of 12.5 million units at a price of $0.12 per unit, to raise $1.5 million (http://cnw.fm/DK0u6). Each unit comprises one common share of the company and one common share purchase warrant. The warrant entitles the holder to purchase one common share at a price of $0.15 for a period of five years from closing. No finder’s fee was paid on this placement, and all securities issued are subject, in accordance with securities laws, to a four-month plus one day holding period from date of issue.

Global Hemp Group intends to use the proceeds for several purposes. Firstly, the capital will be used to fund the development of its New Brunswick hemp cultivation and extraction project. In conjunction with its joint venture partner, Marijuana Company of America (OTC: MCOA), Global Hemp Group completed its industrial hemp trials in northeast New Brunswick at the end of 2017. This marked the first harvest of hemp on the Acadian peninsula in 20 years. The partners have recruited hemp farmers to work 125 acres in 2018 and plan to increase the area under cultivation to over 1,000 acres within three years. Global Hemp will supply its considerable technical and management expertise for this project.

The proceeds will also be used to fund due diligence on potential acquisitions, namely in the State of Oregon, where Global Hemp Group is contemplating buying land for hemp cultivation and cannabinoid extraction. The funds will also be used to bolster the company’s working capital. Company insiders subscribed for a total amount of $371,542, representing 24.8 percent of the private placement.

Founded in 2014, Global Hemp Group is building a strategic portfolio of hemp-based companies to provide its global customer base with a consistent supply of high-quality hemp-derived products. It intends to leverage the huge market potential of hemp products to deliver significant ROI to its shareholders. The number of products that can be manufactured from the hemp plant is vast. It can be used to provide food, clothing, building materials, fuel and medicine. Additionally, its use for the development and production of cannabidiol (CBD)-based medical products has immense market potential. In the future, Global Hemp Group intends to establish several Hemp Agro-Industrial Zones (HAIZ) for the development of industrial hemp cultivation and processing facilities. The company plans to achieve the development of this concept through joint ventures, partnerships or acquisitions of companies involved in the farming, processing, manufacturing and distribution of hemp products.

The market for CBD-based medical products has witnessed a huge surge over the last year, and it is expected to grow at a CAGR of more than 39 percent over the next four years. The Hemp Business Journal (http://cnw.fm/0D2nh) forecasts that the CBD market will grow to over $2 billion by 2020, with $450 million attributed to hemp-based cannabinoid medical products.

For more information, visit the company’s website at www.GlobalHempGroup.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Earth Science Tech, Inc. (ETST): Transparency, Scientific Research and Future Products

  • Received grant from Government of Québec through Canno Inno Laboratories subsidiary
  • Canna Inno Laboratories enhances collaboration between the company’s resources in Canada and the U.S. while providing access to grants
  • Sound scientific research and transparent studies

Earth Science Tech, Inc. (OTC: ETST), a Florida-based biotechnology company focused on cannabis, industrial hemp and cannabinoid research and development for nutraceuticals, pharmaceuticals and medical devices, announced last week that its subsidiary, Canna Inno Laboratories Inc., has received a grant from the Government of Québec for innovation in the pharmaceutical industry. ETST plans to apply for additional funding under Canada’s Scientific Research and Experimental Development Tax Credit program (http://cnw.fm/Q2v2O).

Earth Science Tech formed Canna Inno Laboratories, Inc. in 2017. Strategically headquartered in Montreal, Quebec, it allows Earth Science Tech access to Canadian government and private grants offered to companies for innovation in the pharmaceutical industry. The awarded grant will support the pre-launch process of Earth Science’s three CBD-based products. These nutraceutical products aim to prevent common causes of cancer and help reduce occurrence rates. The pre-launch process includes a series of pre-clinical in vitro trials to fight breast cancer and neurodegenerative disorders. Once complete and patent pending, these high-grade hemp CBD oil products will be commercialized as nutraceuticals and provide alternative natural treatment solutions.

Through the in vitro study with the University of Central Oklahoma and DV Biologics, ETST has provided results that confirm the positive effect of its CBD on breast cancer, immune cell function and human brain cells. The goal of ETST is to discover solutions for conditions that currently have no effective treatment, targeting diseases in which the benefits of CBD have already been demonstrated by researchers worldwide. ETST seeks to increase the effectiveness of cannabinoids and/or CBD and thereby improve treatments for different diseases. The company focuses on providing sound scientific research and transparency on the progression of studies done on its highest quality and purity, full spectrum high-grade hemp CBD products.

For more information, visit the company’s website at www.EarthScienceTech.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) Finding Ever-Growing Ways to Administer Cannabis Benefits

  • Pivot Pharmaceuticals developing disruptive formulations for cannabis-infused markets
  • Company’s goal is to strengthen dosage predictability and improve product stability
  • Recent acquisitions and planned acquisitions give Pivot vertical position in multi-billion-dollar industries

Despite recent setbacks to efforts seeking broader marijuana legalization in North America (http://cnw.fm/zM2Mc), the tide of social preferences for cannabis availability, even in recreational applications, continues to advance (http://cnw.fm/tT62e). Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) is helping to advance efforts to legitimize the drug’s use, both in medicinal and recreational settings, by pursuing ever-increasing methods for consuming cannabis’s derivatives in quantities with predictable outcomes.

“Pivot’s goal is to increase cannabinoid bioavailability, drug release rates and improve product stability, and consumers should be able to confidently take correct and accurate doses to help meet their health and wellness needs,” Joseph Borovsky, Pivot’s vice president of product formulation, stated in a recent news release (http://cnw.fm/ji5nV).

The company has filed continuation patents to maintain its impetus in making cannabis available through powdered formulations that can be combined with existing products in the food and beverage market. That includes health and wellness products such as natural sleep-aids, cold medications and vitamins.

On March 6, Pivot Pharmaceuticals announced its acquisition of Thrudermic, LLC, a North Carolina company invested in a transdermal lipid-based nano-dispersion technology to make cannabis formulations available through external delivery. Thrudermic has filed three new patent applications for Pivot related to better formulation and delivery of its product as the company pursues new routes of drug administration.

Pivot’s acquisition of California’s ERS Holdings, LLC in February not only strengthened its options for enhanced health and wellness products; the move gave the company added visibility to beverage makers such as beer companies working to mitigate a potential decline in profits as their customers divert discretionary income from alcohol consumption to cannabis consumption.

“The (Ready-To-Infuse-Cannabis technology) family of patents will be transformational for the food and beverage industry. Based on our interaction with key players in the beverage market, we anticipate that there will be a significant substitution in consumer choices towards cannabis infused drinks. With this acquisition, we have positioned Pivot to be at the forefront of this enormous new market,” Pivot CEO Patrick Frankham stated in a news release about the acquisition (http://cnw.fm/1xDEK).

The company has also announced plans to acquire Agro-Biotech, a Quebec-based Canadian-licensed cannabis producer (http://cnw.fm/av6uC). Agro-Biotech operates a licensed hydroponic cannabis production facility that can turn out 10,000 kilograms per year, giving Pivot a source for its products as it strives to achieve a stronger vertical position in the industry for cannabinoids, cannabidiol (CBD) and tetrahydrocannabinol (THC).

An agreement between Pivot and Germany’s Solmic Research GmbH gave the company rights to technology designed to give cancer patients relief from vomiting, nausea, neutropenia and anemia during chemotherapy treatment. Those side effects trouble an estimated 70 to 80 percent of chemotherapy patients and often lead to the discontinuation of treatment before the illness has been completely addressed, according to Transparency Market Research (http://cnw.fm/1N15u). Cannabis’s therapeutic abilities are expected to help it grow into a $55.8 billion market by 2025, according to a 2017 report by Grand View Research (http://cnw.fm/F3jWv), and the cancer supportive care products market is expected to reach $29.87 billion by 2021.

For more information, visit the company’s website at www.PivotPharma.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Linker Tech Mimics Body’s Production of Pain Relieving Peptides

  • Developing pain relievers that mimic body’s natural pain relief peptides
  • Other programs include development of treatments for diabetes, synthetization of blue scorpion venom and study of a novel cannabinoid delivery platform
  • Revenues from international licensing strategy

The discovery of endomorphins in 1997 was a remarkable reminder of the human body’s wondrous nature. Endomorphins are naturally produced morphine-like substances with an affinity for the µ-opioid receptors in the brain, which fortunately happen to be the best places to alleviate pain. With a potency that far exceeds morphine, these endogenous substances are the body’s first line of defense against pain and stress. Since their discovery, efforts to replicate them in the lab have been underway, and a number of those initiatives are now bearing fruit in R&D establishments. A signal example is the biotechnology developed by Dr. Harry Parekh, which provides a drug development platform for PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H). Using it, the health sciences company plans to develop endomorphin analogs which, unlike opioids, aren’t addictive and don’t trigger the respiratory depression that all too often causes fatal overdosing.

The development of this new class of pain relieving drugs could usher in an era of more temperate painkillers. Opioids are effective in reducing pain, but their use is blighted by possibilities of sinister side effects. Since they delay the functioning of the body’s respiratory apparatus, the peril of fatal overdose is ever-present. In addition, their efficacy diminishes over time as the body develops resistance to their action, and, thus, larger doses are required for relief. Unfortunately, bigger doses can kill. However, peptide-based pain relievers are devoid of these defects and so offer safer regimens of pain management to patients. Moreover, by employing them as rehab tools to ease the pangs of withdrawal, a lifeline might be thrown to those addicted to opioids.

The linker technology that underlies PreveCeutical’s drug development platform was developed at the University of Queensland in Australia. At that impressive institution, Dr. Parekh headed a team that developed synthetic molecules capable of mimicking the endomorphins produced by the body for pain relief, as explained by PreveCeutical chairman and CEO Stephen Van Deventer in a recent video interview (http://cnw.fm/YN6qR). Although they are as potent as morphine, the effect of these endomorphins is transitory, since they metabolize in seconds. However, Dr. Parekh’s linker technology stabilizes those molecules, allowing them to be used as drugs while maintaining and enhancing their efficacy.

As a result, a number of lead candidates are in the pipeline, since the technology offers an opportunity not just to develop anodynes but also to expand the range of drug delivery methods beyond injection to oral ingestion, for example. Notably, pain management regimens are safer, because the substances aren’t addictive and the body doesn’t develop a tolerance to them. To explore the potential of the technology further, a two-year program has been launched to discover more peptides, expand the library of these peptides and launch pre-clinical trials.

In addition to the development of safer pain reliever, PreveCeutical has three other major programs underway. The first involves the infusion of cannabinoids into a soluble gel. This Sol-gel technology, also a brainchild of Dr. Parekh, was developed at the University of Queensland, which has agreed to license it to PreveCeutical. However, while the Sol-gel technology belongs to the University, its application to infusion of cannabinoids is covered by IP owned by PreveCeutical. A second program is exploring ways to synthesize blue scorpion venom, already used as a biomarker or “tumor paint” in surgery. A third is a four-year program designed to explore how these gene therapies may be used to treat type 2 diabetes and obesity. An editorial and companion audio press release featuring PreveCeutical’s focus on gene therapies is now available on NetworkNewsWire (http://cnw.fm/Iaw7a).

PreveCeutical has appointed Dr. Maher Khaled as director of international operations. Khaled will lead PreveCeutical’s commercialization efforts for its growing portfolio of intellectual property (http://cnw.fm/Rh5lK). For many years an investment manager with the Enterprise Seed Funds of Cambridge University in the United Kingdom, Khaled has been successfully commercializing therapeutic and diagnostic technologies for over a decade.

For more information, visit the company’s website at www.PreveCeutical.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Global Payout Inc. (GOHE) has Many Fingers in the Fintech Pie

  • Global Reserve Platform offers ‘Banking-in-a-Box’ web-based technology
  • Capability to provide a wide range of financial product solutions
  • Strategic focus on freight forwarding and shipping

In the 16th century, the Belgian city of Antwerp, enthused by the entrepreneurial spirit of its burghers, became ‘the center of the entire international economy’. That innovative force made the city the diamond capital of the globe and the location of the world’s oldest stock exchange building, which is in operation to this day. The port of Antwerp, one of the largest in the world, is testing a blockchain system designed to make the handling of containers more efficient and secure. Developments like these herald the ‘rise of the smart port’, according to one commentator (http://cnw.fm/Mn4Dd), for it shows the immense potential of fintech and blockchain to streamline the multitude of processes involved in shipping freight. Reducing the frictions encountered in logistics, shipping and freight forwarding is a major goal of Global Payout Inc. (OTC: GOHE), as well. The company has established a division to provide fintech services to underserved supply chain entities. Through it, Global Payout offers freight forwarders, government contractors, motor carriers, customs brokers, and third party logistic providers online access to funds for working capital.

Global Payout has already made its mark in the fintech industry. Its menu of offerings ranges over a variety of state-of-the-art software solutions aimed at companies involved in processing money remittances, wire transfers, bill payments, business-to-business payments, currency exchange, e-wallet payments and other types of financial transactions. Fortified by a collaboration with First American Electronic Payment Solutions, Inc., the company was able to introduce a customizable, ‘banking-in-a-box’ web-based platform. Its Global Reserve Platform (“GRP”) offers the capability to execute the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers and is expected to improve workflow, operational efficiencies and global financial management for enterprises operating across the globe.

Recently, Global Payout published details of a joint venture agreement between its majority-owned subsidiary, MoneyTrac Technology, Inc. (“MTRAC”), and GreenBox POS, LLC (“GBOX”) (http://cnw.fm/38RjF). GBOX is a technology company that builds end-to-end suites of financial products that can benefit almost any industry. Churning out a string of innovations, the software developer has been awarded five provisional patents for its technologies. The company has the capability to modify existing point-of-sale systems and is presently offering custom-built blockchain kiosk machines. Under the terms of the agreement, MoneyTrac will provide sales and marketing support to GBOX.

MoneyTrac has been cutting other deals, too. Last year, it signed an agreement with H Smart Inc. under which H Smart Inc. will use MTRAC’s financial technology platform. H Smart, a division of Marijuana Company of America (OTC: MCOA), is a developer and distributor of innovative wellness and cannabidiol products. The technology available on MTRAC’s platform, employing software developed and provided by MTRAC, will allow H Smart to pay commissions to its affiliates (http://cnw.fm/GbJb5).

As Global Payout expands its network of business partners, its revenue streams multiply. The company continues to explore avenues through which its payment and transaction processing systems may reduce costs and improve client satisfaction, such as freight forwarding and shipping. Shipping a container typically involves over 20 different parties and over 100 different transactions. Since many of these interactions are carried out by email, phone and fax, paperwork accounts for a substantial part of container transport costs. However, blockchain solutions like those being developed by Global Payout could limit intermediary involvement and thus substantially reduce transaction costs.

For more information, visit the company’s website at www.GlobalPayout.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Pressure BioSciences’ (PBIO) Patented Tech Enhances Nanoemulsion Bioavailability and Extends Product Shelf Life

  • Patented UST process produces highly stable, clean and cost-effective nanoemulsions
  • Technology can be applied across many industries, including pharmaceutical, food, nutraceutical, industrial lubricant, paint and cosmetic sectors
  • UST technology aligns with consumer demand for chemical- and preservative-free products

The demand for nanoemulsions is growing at a fast pace, with potential applications in many industry sectors, including food, pharmaceuticals, nutraceuticals, cosmetics and industrial lubricants. Up to now, one of the major problems with nanoemulsions has been their instability. This instability compromises the bioavailability and absorption of active ingredients for product preparation and the shelf life of the product. Life sciences company Pressure BioSciences Inc. (OTCQB: PBIO) is positioned to change this landscape via a patented novel technique called Ultra Shear Technology (“UST”). This technology uses intense shear forces generated by high-pressure valve discharge, which can help produce nanoemulsions that exhibit significantly improved absorption, greater stability and increased bioavailability compared to traditional micro and macro-emulsions.

Emulsions are mixtures of two liquids which are largely immiscible without the aid of emulsifying chemicals, such as surfactants. Surfactants assist in the dispersion of one liquid within the other, where it exists as tiny droplets. The smaller the droplet size for any given volume of dispersed liquid, the greater the absorption and bioavailability of active compounds. Nanoemulsions produce dispersed droplets with exceptionally small diameters, measured in nanometers.

To date, cost-effective, highly stable nanoemulsions made with minimal or no surfactants have been difficult to produce. Pressure BioSciences’ UST enables manufacturers to produce nanoemulsions at industrial scale levels that virtually exclude the use of surfactants, leading to safer and more effective oral delivery of food and medical products. This is a big deal in today’s world, where consumers across the globe are focusing more on wellbeing and demanding food that is appealing, tastes good, is free of chemicals and is safe to eat. Nanoemulsions produced using UST facilitate the production of food products with enhanced shelf lives and without the need for chemicals or preservatives. This groundbreaking technology will also increase product quality and shelf life in the pharmaceutical, nutraceutical and cosmetic sectors.

In October 2017, Pressure BioSciences concluded a strategic collaboration agreement with Phasex Corporation that will allow for the production of stable, water-soluble nanoemulsions that are expected to significantly improve drug and active ingredient delivery in the pharmaceutical, nutraceutical and cannabis oil industries. Aqueous nanoemulsions have the potential to increase the absorption and bioavailability of water-insoluble compounds like vitamin A, vitamin C and cannabinoids such as CBD. Phasex’s expertise lies in supercritical fluid (“SCF”) extraction processes that can be used for the manufacture of an extensive range of fine chemicals, polymers and natural extracts for pharmaceutical and nutraceutical formulations. SCF technology enables solvent-free extraction of active ingredients, which substantially enhances the quality of nanoemulsions.

Although the UST platform offers very exciting opportunities for future growth, Pressure BioSciences is not dependent on its novel UST platform for its future success. To that point, the company has been showing solid growth over the past several years in its’ primary product line, which is based on its innovative, patented, enabling platform called Pressure Cycling Technology (“PCT”). This technology uses cycles of hydrostatic pressure from ambient to ultra-high pressure levels to control bio-molecular interactions. It can be applied in several emerging life science areas, including:

  • Sample preparation for genomic, proteomic and small molecule studies
  • Control of biochemical reactions
  • Protein purification
  • Pathogen inactivation
  • Immunodiagnostics

Patents for this technology have been issued to PBIO from many countries around the world, including China, Japan, multiple European countries, Canada, and the U.S. To date, the company has installed almost 300 PCT systems in more than 150 pharmaceutical, academic, biotechnological and government laboratories worldwide. Primary applications for the technology are in biomarker discovery, forensics, pathology and agriculture. The company has reported annual revenue of greater than $2 million, even though it has had but one sales person and one PCT instrument to sell. Recently, however, the company added four additional sales reps and has announced plans to release up to four additional instruments in 2018. These changes have set the company up for what could be significant future growth and an excellent return on investment for shareholders.

For more information, visit the company’s website at www.PressureBioSciences.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

ChineseInvestors.com, Inc. (CIIX) Turns Focus to Growth of Cryptocurrency and Blockchain Technology, Financial Consulting Division

  • Company returning to its roots in financial consulting, corporate brand building and educational services for cryptocurrencies, such as bitcoin
  • CIIX has daily video from NYSE targeted at its global Chinese-speaking investment community titled ‘Bitcoin MultiMillionaire’ and hosts a bitcoin ATM in the lobby of its San Gabriel, California, headquarters
  • Company is urging its shareholders to convert stock, on a four-for-one basis, for a share in the new, private company that includes hemp assets CBD Biotechnology Co. Ltd., Hemp Logic, Inc. and ChineseHempOil.com, Inc.

ChineseInvestors.com, Inc. (OTCQB: CIIX) will return to its roots as a financial consultant and a specialist in cryptocurrency, especially bitcoin, as it spins off its hemp assets into a private company. In a news release (http://cnw.fm/i7zeW), Paul Dickman, CFO of CIIX, said, “This is a great time to spin off CIIX’s CBD focused assets as we continue to explore new ways to expand its core financial services business, including its recent move into the cryptocurrency and blockchain technology industry.”

CIIX has in the past succeeded as a diverse company with multiple-focuses, but, with this spinoff, it can now concentrate on its core skills in brand building for startups and financial marketing for its clients.

The San Gabriel, California-based company specializes in financial education and marketing for the global Chinese-speaking investment community. It has an interest in the growth of cryptocurrency with a daily video newscast from the NYSE daily titled ‘Bitcoin MultiMillionaire’ and hosts a bitcoin ATM in the lobby of its San Gabriel, California, headquarters.

Following the planned spinoff, CIIX intends to focus on those interests while giving its shareholders a special dividend. They may exchange four shares of CIIX common for one share in the new company, which consists of CIIX’s hemp-related assets. These include wholly owned foreign enterprise CBD Biotechnology Co., Ltd. and U.S.-based wholly owned subsidiaries Hemp Logic, Inc. and ChineseHempOil.com, Inc.

The four-for-one exchange of shares will be made effective on May 31, 2018, the date of the spinoff. The new company will initially be private, but CIIX has announced plans to bring the new company into the public market in the 12-18 months that follow (http://cnw.fm/MCe3G).

For more information, visit the company’s website at www.ChineseInvestors.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Earth Science Tech, Inc. (ETST) Enlarges Its Footprint in Hemp-Based CBD Market

  • Agreement with Mr. Checkout will significantly strengthen the company’s product distribution network
  • Human trials launched evaluating CBD-based therapy for opioid addiction
  • Application made to uplist to OTCQB in early 2018, attracting more investment

The worldwide cannabidiol (CBD) oil market, which includes products derived from both marijuana and hemp, is projected to grow at a CAGR of more than 39 percent through 2021. The health benefits of CBD oil are the major driver for growth in this market, with global demand steadily on the rise in recent years. Hemp-based CBD oil products in particular are more popular, as they have a lower concentration of psychoactive compound tetrahydrocannabinol (THC) than those derived from marijuana, therefore not requiring a medical prescription (http://cnw.fm/kaL9i). Earth Science Tech, Inc. (OTC: ETST) is one of the companies that is focused on the development of hemp-based CBD products and has taken a number of steps recently to enlarge its presence in this market sector.

Following a revamp of its CBD product line, Earth Science Tech announced on February 13, 2018, that it had concluded an agreement with Mr. Checkout for the distribution of its products via major retailers and stores across the United States. This agreement will strengthen the company’s distribution network, which currently has 10 active representatives targeting distribution to health food stores and clinics. Mr. Checkout is a national group of independent distributors of products to over 60 major retailers and 55,000 stores. It will market ETST’s product line to major retailers such as Walmart, Walgreens and Target.

Earth Science Tech is a biotechnology company focused on the research and development of hemp-based CBD products for the pharmaceutical and nutraceutical industries. It also has a focus on the development of diagnostic tools and medical devices. On February 28, 2018, the company announced that it had finalized plans to conduct human trials on its new CBD-based formulation that targets opioid addiction (http://cnw.fm/rNnQ0). These trials will assess the efficacy of the combination of hemp-based CBD oil with an essential mineral element. Currently, the sole therapy for this condition is a monotherapy based on an essential mineral element. ETST’s formulation is expected to increase the potency and improve the outcome of this therapy.

The company operates through three wholly owned subsidiaries:

  • Cannabis Therapeutics, Inc. which develops leading edge, cannabinoid-based products for the pharmaceutical and nutraceutical sectors;
  • KannaBidioiD which is focused more on developing products for the recreational use of cannabis, including edibles, vapes and eLiquids;
  • Earth Science Pharma, Inc., which develops medical devices and low-cost, noninvasive diagnostic tools, as well as testing processes and vaccines for sexually transmitted diseases.

Cannabis Therapeutics is in the development stage of two CBD-based pharmaceutical drugs and three CBD-based nutraceutical products. These will target a variety of ailments, including depression, anxiety, breast cancer and fatty liver disease. In October 2017, Earth Science Tech announced a collaboration with Clinique SIDA Amité to conduct a mini-trial on its MSN-2 device for the detection of Chlamydia. ETST has also acquired Canna Inno Laboratories Inc., based in Montreal, Canada, which will give the company the opportunity to expand into Canada and gain access to local government grants for pharmaceutical industry innovation.

Earth Science Tech expects to uplist to the OTCQB Venture Exchange in early 2018, which it believes will attract well-funded institutional investors. These recent developments are likely to increase company growth and enlarge Earth Science Tech’s presence in the cannabis industry.

For more information, visit the company’s website at www.EarthScienceTech.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Building a Portfolio of Industrial Hemp Companies is Key to the Future of Global Hemp Group, Inc. (CSE: GHG) (FRA: GHG) (OTC: GBHPF)

  • Global Hemp Group will employ joint ventures, partnerships, and acquisitions to capture cash flow, generate revenues and create value for its shareholders
  • Global Hemp Group will be involved in the cultivation, processing and distribution of industrial hemp to domestic and international markets
  • At the end of 2017, GHG issued its final report on the first year of its joint venture to produce industrial hemp on the Arcadian Peninsula of New Brunswick, Canada

Global Hemp Group, Inc. (CSE: GHG) (FRANKFURT: GHG) (OTC: GBHPF) is focused on the vital role that industrial hemp will play in building a sustainable future. The company concentrates on the production and processing of hemp to produce raw and finished goods for domestic and international markets.

Through a series of partnerships, joint ventures and acquisitions, Global Hemp Group seeks to build a strategic portfolio of forward-thinking companies that also believe in the disruptive potential of the industrial hemp plant (http://cnw.fm/kd4OB). The company is headquartered in Vancouver, British Columbia, and is actively seeking additional projects in the hemp cultivation and cannabinoid extraction space in Canada and the United States.

Global Hemp Group, in partnership with Marijuana Company of America (OTC: MCOA), recently completed industrial hemp trials, in 2017, which marked the first hemp cultivation on the Arcadian Peninsula of New Brunswick, Canada in 20 years. The joint venture partners plan to begin commercial cultivation of industrial hemp in 2018, including plans to acquire equipment for the extraction of cannabinoids (CBD, CBG, CBN and CBC). Experienced hemp farmers have been recruited to grow on 125 acres in 2018, with plans to cultivate more than 1,000 acres by year three of the project. Global Hemp Group is to provide technical and management expertise to the joint venture.

What makes industrial hemp unique is its ample potential for aiding in the manufacture of thousands of sustainable products across a wide range of markets. To qualify as industrial hemp, regulation in the United States and Canada requires less than 0.3 percent Delta 9 Tetrahydrocannabinol (THC) content, the psychoactive ingredient in cannabis.

Hemp has tremendous value as an agricultural crop and industrial solution that can not only produce food and clothing on an industrial scale, but also has the potential to become the base product to develop, amongst other things, super-foods, textiles, building materials, bio-fuels and plant-based medicine. Oil-based products such as bio-plastics, cosmetics, sealants and cleaning products also provide an opportunity for hemp to find new global markets.

Industrial hemp plays a fundamental role in the development of sustainable industrial solutions. Global Hemp Group, with its knowledge and expertise, is building a strategic portfolio of companies with the objective of delivering shareholder value through joint ventures, partnerships and acquisitions.

For more information, visit the company’s website at www.GlobalHempGroup.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net